ArticleMolecular cancer therapeutics2013
Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
Article in Molecular cancer therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 99 citations in OpenAlex.
- Clickable polyamidosaccharides: accessing bottlebrush inspired hyaluronic acid glycopolymers for CD44 targeting of breast cancer cells.Biomaterials science · 2026Article
- Hyaluronan like polysaccharide based nanodrugs with enhanced CD44 avidity for image-guided drug delivery to breast cancer.RSC advances · 2026Article
- Green-Synthesized Hyaluronic Acid-Conjugated Fluorescent Graphene Quantum Dots for Bioimaging and Cancer Theranostics: Synthesis, Characterization, and Cytotoxicity Assessment.Journal of fluorescence · 2025Article
- Innovative Design of Targeted Nanoparticles: Polymer-Drug Conjugates for Enhanced Cancer Therapy.Pharmaceutics · 2023Review
- How to Develop Drug Delivery System Based on Carbohydrate Nanoparticles Targeted to Brain Tumors.Polymers · 2023Review
- Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis.Therapeutic advances in medical oncology · 2023Review
- Preclinical Models of Brain Metastases in Breast Cancer.Biomedicines · 2022Review
- In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment.International journal of nanomedicine · 2022Article
- The blood-tumour barrier in cancer biology and therapy.Nature reviews. Clinical oncology · 2021Review
- Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer.Materials today (Kidlington, England) · 2021Article
- Bioactive nanotherapeutic trends to combat triple negative breast cancer.Bioactive materials · 2021Review
- ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody.JCI insight · 2021Article
- Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.International journal of molecular sciences · 2021Review
- Design Challenges in Polymeric Scaffolds for Tissue Engineering.Frontiers in bioengineering and biotechnology · 2021Review
- Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.Cancer research · 2020Review
- Review
- Autocatalytic Delivery of Brain Tumor-targeting, Size-shrinkable Nanoparticles for Treatment of Breast Cancer Brain Metastases.Advanced functional materials · 2020Article
- Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.Molecular pharmaceutics · 2020Article
- Hyaluronan impairs the barrier integrity of brain microvascular endothelial cells through a CD44-dependent pathway.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Article
- Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
Brain (central nervous system; CNS) metastases pose a life-threatening problem for women with advanced metastatic breast cancer. It has recently been shown that the vasculature within preclinical brain metastasis model markedly restricts paclitaxel delivery in approximately 90% of CNS lesions. Therefore to improve efficacy, we have developed an ultra-small hyaluronic acid (HA) paclitaxel nanoconjugate (∼5 kDa) that can passively diffuse across the leaky blood-tumor barrier and then be taken up into cancer cells (MDA-MB-231Br) via CD44 receptor-mediated endocytocis. Using CD44 receptor-mediated endocytosis as an uptake mechanism, HA-paclitaxel was able to bypass p-glycoprotein-mediated efflux on the surface of the cancer cells. In vitro cytoxicity of the conjugate and free paclitaxel were similar in that they (i) both caused cell-cycle arrest in the G2-M phase, (ii) showed similar degrees of apoptosis induction (cleaved caspase), and (iii) had similar IC50 values when compared with paclitaxel in MTT assay. A preclinical model of brain metastases of breast cancer using intracardiac injections of Luc-2 transfected MDA-MB-231Br cells was used to evaluate in vivo efficacy of the nanoconjugate. The animals administered with HA-paclitaxel nanoconjugate had significantly longer overall survival compared with the control and the paclitaxel-treated group (P < 0.05). This study suggests that the small molecular weight HA-paclitaxel nanoconjugates can improve standard chemotherapeutic drug efficacy in a preclinical model of brain metastases of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.